Home » QIDP Antibiotics » Page 7

Category Archives: QIDP Antibiotics

All AllPhasePharma blogs dealing predominantly with a QIDP antibiotic

Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs

Posted on by — No Comments ↓

Several interesting articles appeared recently which shed light on the efficacy of eravacycline and the safety of omadacycline, both in Phase 3 and both in a head-to-head race to the market.  Well, the term ‘race’ is bit of a stretch as both drugs have seen very significant delays in development. Omadacycline from Continue reading Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs→

Choose your Outcome: How Design Minutiae Affect Trial Results

Posted on by — No Comments ↓

When you search for ‘ceftidoren’ on Wikipedia, you will get a surprise: there is no entry. However, a search on the web tells us that Spectracef (ceftidoren pivoxil) still exists. Gee, now the drug is spelled ‘cefditoren’ and – looking through the list of retrieved articles – it seems that Continue reading Choose your Outcome: How Design Minutiae Affect Trial Results→

AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug

Posted on by — No Comments ↓

At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers mention a peculiar MoA for this gyrase/topoisomerase Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug→